Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-0332991 in Advanced Hepatocellular Carcinoma
NCT01356628Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2011
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in hepatocellular carcinoma (HCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Time to Disease Progression up to 100 months. Started May 2011; status: completed.
02
Drugs
palbociclib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01356628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356628.